Changes in Revenio Group Corporation's own shares

Revenio Group Corporation | Stock Exchange Release | September 21, 2026 at 17:00:00 EEST

Revenio Group Corporation has on September 21, 2026, transferred 10,146 Company’s treasury shares (REG1V) to the members of the Board of Directors as part of the remuneration of the Board.

Revenio Group Corporation's AGM decided on May 12, 2026, that approximately 40 percent of the Board members' annual remuneration (gross) will be settled in the form of the company’s shares held in its treasury, however not exceeding a maximum of 11,200 shares in total, while approximately 60 percent will consist of a monetary payment. Tax will be deducted from the monetary payment, calculated on the amount of the entire annual remuneration.

The AGM decided annual remuneration be paid to the members of the Board of Directors for the term of office ending at the close of the Annual General Meeting 2027 as follows: EUR 70,000 to the Chair of the Board, EUR 45,000 to any Vice Chair of the Board, EUR 35,000 to the members of the Board, EUR 15,000 to the Chair of the Audit Committee, EUR 10,000 to the Chair of the Nomination and Remuneration Committee, and EUR 5,000 to the members of the Board committees. In addition to the above, the Chair of a potentially established Technology Committee EUR 10,000 and its members EUR 5,000, as well as the Chair of a potentially established Integration Committee EUR 20,000 and its members EUR 5,000. The share payment will be valued using the weighted average value of the share on the day following the release of the half-year financial report 1 January–30 June 2026.

Revenio Group Corporation now holds a total of 65,704 of its treasury shares.

For further information, please contact
CFO Jukka Kainulainen
+358 9 8775 1150
ir@revenio.fi

Distribution
Nasdaq Helsinki Oy
Financial Supervisory Authority (FIN-FSA)
Principal media
www.reveniogroup.fi/en 

Revenio Group in brief
Revenio is a leading turnkey solutions provider in the global eye care market. The group offers fast, user-friendly, and reliable tools for diagnosing a wide variety of eye diseases. Revenio’s solutions include e.g. tonometers, fundus imaging devices, optical coherence tomography (OCT), perimeters, multimodal devices, refraction systems, and software solutions under iCare and Visionix. 

In May 2026, Revenio joined forces with Visionix, creating the most innovative, creative and comprehensive entity serving eye care professionals across optometry, optical retail and ophthalmology. In 2025, the Group’s net sales totaled EUR 109.7 million, with an operating profit of EUR 25.4 million. In 2025, the Group’s pro forma net sales totaled EUR 252.8 million, with a pro forma adjusted EBITDA of EUR 45.3 million. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V.